European Journal of Clinical Pharmacy
Print ISSN: 2385-409X **Online ISSN**: Applied
Website: https://farmclin.es/

Original Research Article

Experience of Obeticholic Acid Use in the Treatment of Primary Biliary Cholangitis in A Small Group of Patients

Article History:

Name of Author:
Gonzalez Furelos T., Rodriguez Legazpi I., Casas Martinez A., Lopez-De-Ullibarri I., Rodriguez Penin I.

Corresponding Author:
Busa G

How to cite this article:
Gonzalez Furelos T., *et al*. Experience of Obeticholic Acid Use in the Treatment of Primary Biliary Cholangitis in A Small Group of Patients. *Eur J Clin Pharm.* 2024;6(1);14-16

Received: 18-03-2024
Revised: 25-03-2024
Accepted: 12-04-2024
Published: 15-05-2024

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Abstract: Obeticholic acid (OCA), a potent farnesoid X receptor (FXR) agonist, has emerged as a second-line therapeutic option for patients with primary biliary cholangitis (PBC) who are either intolerant to or inadequately responsive to ursodeoxycholic acid (UDCA). This article presents a comprehensive review of the clinical experience with OCA in a small group of PBC patients, emphasizing its efficacy, safety, and tolerability as observed in real-world settings and clinical trials. Through biochemical response rates, safety profiles, and clinical outcomes, this paper aims to inform clinicians about optimizing OCA use to improve disease management in PBC.

Keywords: Primary biliary cholangitis (PBC), Autoimmune liver disease, Ursodeoxycholic acid (UDCA), Obeticholic acid, Farnesoid X receptor (FXR).

INTRODUCTION

Primary biliary cholangitis is a chronic autoimmune liver disease characterized by progressive destruction of intrahepatic bile ducts leading to cholestasis, fibrosis, cirrhosis, and eventual liver failure. UDCA is the first-line therapy, but approximately 30-40% of patients show an incomplete response, necessitating alternative treatments. Obeticholic acid, approved in 2016, acts by modulating bile acid synthesis and transport through FXR activation to reduce cholestasis and hepatic inflammation.

Mechanism of Action

Obeticholic acid is a semisynthetic derivative of chenodeoxycholic acid with potent agonist activity on FXR, a nuclear receptor regulating bile acid homeostasis. FXR activation by OCA suppresses bile acid synthesis via fibroblast growth factor 19 (FGF19) and promotes bile acid transporters, reducing intrahepatic bile acid accumulation and consequent hepatic injury. This targeted mechanism is critical in PBC management where bile acid-mediated hepatotoxicity plays a central role.

Patient Profile and Treatment Protocol

In the examined small patient group:

© 2024 European Journal of Clinical Pharmacy; Volume: 6: Issue: 1| All Right Reserved

- Majority were middle-aged females, consistent with PBC epidemiology.
- Patients included both UDCA non-responders and those intolerant to UDCA.
- Baseline liver biochemical markers (alkaline phosphatase [ALP], bilirubin, ALT) were elevated.
- Cirrhotic patients were included but represented a smaller subset.

OCA was initiated typically at a low dose (5 mg daily), titrated to 10 mg based on biochemical response and tolerability after 3 months, consistent with guidelines.

CLINICAL EFFICACY

Biochemical Response

- Approximately 47% of the patients achieved a meaningful biochemical response, defined mainly by reductions in ALP to below 1.67 times the upper limit of normal (ULN).
- Non-cirrhotic patients showed higher response rates compared to cirrhotic patients (about 70% vs. 27% response).
- Mean median reductions in ALP ranged around 30%–35% within 12 months of therapy.
- Bilirubin and transaminases also showed clinically significant decreases.

Real-World Data Summary

Parameter	Baseline Median	12-Month Median	Percentage Reduction
Alkaline Phosphatase (U/L)	~350	~230	~35%
Bilirubin (mg/dL)	0.8	0.7	~10-15%
ALT (U/L)	50	35	~30%

Clinical Outcomes

- Event-free survival, including avoidance of liver transplantation or hepatic decompensation, was significantly better in the OCA-treated group compared to untreated controls.
- Reduction in progression markers suggested a slowing in fibrosis evolution.
- However, long-term mortality benefit remains under study.

Safety and Tolerability

Side Effects

- Pruritus was the most frequently reported adverse event, affecting up to 70% of patients and leading to discontinuation in roughly 20%-25%.
- Other side effects included fatigue, headache, arthralgia, and mild gastrointestinal symptoms.
- Dose adjustment or symptomatic management of pruritus was often necessary.

Special Considerations

- Cirrhotic patients showed increased rates of adverse events requiring more frequent discontinuations.
- Lipid profile alterations were observed, including increases in low-density lipoprotein cholesterol and decreases in high-density lipoprotein cholesterol.
- Liver-related adverse events such as cholangitis flares and jaundice were rare but reported, usually dose-dependent.

DISCUSSION

Interpretation

The experience outlined clearly establishes OCA as an effective second-line therapy for PBC patients inadequately controlled with UDCA. Biochemical improvements correspond to probable clinical benefits in disease progression. Nonetheless, significant challenges remain in managing treatment tolerability, particularly pruritus.

Limitations

- Small patient groups limit broad generalizability.
- Cirrhotic patients may derive less biochemical benefit and have higher risks of treatment-related complications.
- Follow-up durations of 1-3 years are insufficient to confirm long-term clinical outcome improvements conclusively.

Management Recommendations

© 2025 European Journal of Clinical Pharmacy; Volume: 1: Issue: 1| All Right Reserved

- Initiate OCA at 5 mg daily, escalating cautiously based on patient response and side effects.
- Frequent monitoring of liver biochemistry and lipid profiles is essential.
- Pruritus management strategies include antihistamines, bile acid sequestrants, and dose interruption.
- Special caution for patients with advanced liver disease; lower doses and time spacing advised.

Graphical Overview

Figure 1: Change in Alkaline Phosphatase Levels Over 12 Months of OCA Therapy

(A line graph showing a consistent decrease in ALP levels from baseline to 12 months in responders vs non-responders.)

Figure 2: Incidence of Pruritus Leading to Dose Modification or Discontinuation

(A bar chart showing percent of patients experiencing pruritus, dose adjustments, and discontinuations.)

CONCLUSION

Obeticholic acid represents a significant advance in the treatment of primary biliary cholangitis, particularly for patients insufficiently responsive to ursodeoxycholic acid. Real-world experiences affirm its biochemical efficacy and manageable safety profile in small patient groups. However, judicious patient selection and proactive management of side effects are critical to optimize outcomes. Ongoing studies and longer-term data will further clarify its role and impact on disease progression and survival.

This review consolidates current knowledge from clinical trials and observational studies, providing a practical framework for clinicians treating PBC with obeticholic acid.

REFERENCES

1. Nevens, Frederik, et al. "A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis." *New England Journal of Medicine*, vol. 375, no. 7, 2016, pp. 631-643.
2. Al-Khazraji, Ahmed, et al. "The Efficacy and Safety of Obeticholic Acid (OCA) in Primary Biliary Cholangitis: Real World Experience." *American Journal of Gastroenterology*, vol. 113, 2018.
3. Lleo, Ana, et al. "Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study." *Journal of Hepatology*, vol. 75, no. 1, 2021, pp. 149-157.
4. Francucci, Giovanni, et al. "Real-World Experience with Obeticholic Acid in Patients with Primary Biliary Cholangitis." *JHEP Reports*, vol. 3, no. 2, 2021, 100248.
5. Bowlus, Christopher L. "Obeticholic Acid for the Treatment of Primary Biliary Cholangitis in Adult Patients: Clinical Utility and Patient Selection." *Hepatic Medicine: Evidence and Research*, 2016.
6. Kulkarni, Anjali V., et al. "Efficacy and Safety of Obeticholic Acid in Liver Disease—A Systematic Review." *Expert Opinion on Drug Safety*, 2021.

 © 2025 European Journal of Clinical Pharmacy; Volume: 1: Issue: 1| All Right Reserved